|
시장보고서
상품코드
2102440
원발성 골수섬유증 시장 규모, 점유율 및 성장 분석 : 치료법별, 약제별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Primary Myelofibrosis Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 원발성 골수섬유증 시장 규모는 2024년에 11억 5,000만 달러로 평가되며, 2025년 12억 1,000만 달러에서 2033년까지 47억 2,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 4.82%로 성장할 것으로 전망되고 있습니다.
전 세계 원발성 골수섬유증 시장은 인구 고령화와 혈액 악성 종양에 대한 인식 향상에 의해 JAK 억제제 등의 표적 치료제에 대한 수요가 촉진되면서 점점 더 중요한 위치를 차지하고 있습니다. 기존에는 하이드록시우레아나 수혈에 의존했으나, 선진 지역의 발병률 상승을 배경으로 신약 도입에 힘입어 시장은 크게 진화했습니다. JAK-STAT 조절제 및 병용 요법의 등장으로 비장 축소와 환자의 삶의 질(QOL)이 모두 향상되고 있습니다. 조기 개입을 지원하는 임상 데이터에 힘입어 유연한 치료 프로토콜이 촉진되고 있습니다. 또한 AI를 활용한 신약 개발은 유전체 분석을 통한 약물 설계의 고도화, 환자 군별 최적화, 개발 일정 효율화를 통해 파이프라인에 혁명을 일으키고 있습니다. 이러한 혁신적인 접근 방식은 투자자들의 관심을 불러일으키는 동시에, 치열한 경쟁 환경 속에서 효과적인 치료법에 대한 조기 접근을 보장하고 있습니다.
전 세계 원발성 골수섬유증 시장의 성장 요인
원발성 골수섬유증에 대한 임상적 인식 제고와 진단 능력 향상으로 인해 치료적 개입의 혜택을 받을 수 있는 환자 수가 증가하고 있으며, 그 결과 기존 및 신규 치료법에 대한 수요가 견인되고 있습니다. 의료진은 증상의 양상을 파악하고 적절한 진단 기준을 적용하는 능력을 향상시키고 있으며, 이를 통해 질병 수정 요법의 조기 도입이 촉진되고 있습니다. 이러한 적극적인 태도는 환자의 예후를 개선할 뿐만 아니라, 다양한 의료 환경에서 치료가 확산됨에 따라 시장의 지속적인 성장에 기여하고 있습니다. 그 결과, 의료 기관들은 전문적인 치료 경로에 자원을 투입하고 있으며, 이는 시장의 전반적인 확장을 더욱 지원하고 있습니다.
전 세계 원발성 골수섬유증 시장의 제약 요인
전 세계 원발성 골수섬유증 시장에서 새로 승인된 치료법의 높은 가격 책정은, 특히 보험 급여 옵션이 제한된 지역에서 의료 시스템에 막대한 부담을 주고 있습니다. 보험사는 치료비 지급에 대해 포괄적인 근거를 자주 요구하고 있으며, 이는 환자의 치료 접근을 지연시키고 이용률 저하로 이어질 가능성이 있습니다. 그 결과, 의료 종사자들은 동등한 효능을 가지면서도 더 저렴한 가격의 기존 치료법을 우선시하는 경향이 있으며, 예산을 고려할 수밖에 없는 환경에서는 혁신적인 솔루션의 시장 침투를 방해하고 전반적인 성장을 저해하게 됩니다. 또한 환자와 그 보호자에게 가해지는 경제적 부담은 치료 중단이나 복약 순응도 저하로 이어져 시장 발전을 더욱 저해하고, 치료상 이점을 훼손할 가능성이 있습니다.
전 세계 원발성 골수섬유증 시장 동향
전 세계 원발성 골수섬유증 시장은 표적 유전자 치료의 발전에 힘입어 혁신적인 변화를 겪고 있습니다. CRISPR 및 RNA 간섭 기술의 혁신을 통해 연구자들은 병인성 돌연변이를 편집하고, 질병을 촉진하는 경로를 효과적으로 조절할 수 있게 되었습니다. 이러한 정밀 의료 접근 방식은 생명공학 기업과 학술기관 간의 전략적 제휴를 촉진하고, 규제 당국과의 협력을 강화하는 동시에, 안전성, 유효성 및 장기적인 삶의 질 향상에 초점을 맞춘 환자 중심의 임상 시험 설계를 추진하고 있습니다. 그 결과, 다양한 지역에서 이러한 치료법에 대한 접근성을 확보하는 데 대한 중요성이 커지고 있으며, 치료 패러다임이 더욱 개인화된 효과적인 해결책으로 진화함에 따라 시장은 강력한 성장 궤도에 올라서고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 원발성 골수섬유증 시장 규모 : 치료 유형별
세계의 원발성 골수섬유증 시장 규모 : 약제 유형별
세계의 원발성 골수섬유증 시장 규모 : 투여 경로별
세계의 원발성 골수섬유증 시장 규모 : 유통 채널별
세계의 원발성 골수섬유증 시장 규모 : 최종사용자별
세계의 원발성 골수섬유증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.05Global Primary Myelofibrosis Market size was valued at USD 1.15 Billion in 2024 and is poised to grow from USD 1.21 Billion in 2025 to USD 4.72 Billion by 2033, growing at a CAGR of 4.82% during the forecast period (2026-2033).
The global primary myelofibrosis market is increasingly pivotal due to an aging demographic and heightened awareness of hematologic malignancies, fostering demand for targeted therapies like JAK inhibitors. Historically reliant on hydroxyurea and transfusions, the market has evolved significantly with the introduction of novel agents, propelled by rising incidence rates in developed regions. The emergence of JAK-STAT modulators and combination therapies enhances both spleen reduction and patient quality of life. Clinical data supporting early interventions is encouraging adaptable treatment protocols. Additionally, AI-enabled drug discovery is revolutionizing the pipeline by enhancing drug design through genomic insights, optimizing patient stratification, and streamlining development timelines. This innovative approach is catalyzing investor interest and ensuring quicker access to effective treatments within this competitive landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Primary Myelofibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Primary Myelofibrosis Market Segments Analysis
Global primary myelofibrosis market is segmented by treatment type, drug type, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into JAK Inhibitors, Anemia-Directed Therapies, Stem Cell Transplantation, Supportive Care Therapies and Others. Based on drug type, the market is segmented into Branded Drugs and Generic Drugs. Based on route of administration, the market is segmented into Oral and Injectable/Parenteral. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Care Centers and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Primary Myelofibrosis Market
Increasing clinical awareness and improved diagnostic capabilities for primary myelofibrosis are enhancing the number of patients who can benefit from therapeutic interventions, consequently driving demand for both existing and emerging treatment options. Medical professionals are becoming more adept at identifying symptomatic presentations and applying appropriate diagnostic criteria, which facilitates earlier implementation of disease-modifying therapies. This proactive stance enhances patient outcomes and contributes to continued market growth as treatment uptake broadens across various healthcare environments. As a result, healthcare organizations are dedicating resources to specialized treatment pathways, further bolstering the overall expansion of the market.
Restraints in the Global Primary Myelofibrosis Market
The premium pricing of newly approved treatments in the Global Primary Myelofibrosis market exerts considerable pressure on healthcare systems, especially in areas with limited reimbursement options. Insurance providers frequently demand comprehensive justification for treatment coverage, which can delay patient access and lead to lower usage rates. As a result, healthcare professionals may favor established, more affordable therapies that offer similar effectiveness, hindering the market reach of innovative solutions and stunting overall growth in budget-conscious settings. Additionally, the financial strain on patients and their caregivers can lead to treatment stoppage or poor adherence, further stifling market development and reducing the therapeutic benefits.
Market Trends of the Global Primary Myelofibrosis Market
The Global Primary Myelofibrosis market is experiencing a transformative shift driven by advances in targeted gene therapy. Innovations in CRISPR and RNA interference technologies are enabling researchers to edit pathogenic mutations and effectively modulate disease-driving pathways. This precision medicine approach is fostering strategic collaborations between biotech firms and academic institutions, enhancing regulatory engagement, and promoting patient-centric trial designs focused on safety, efficacy, and long-term quality of life improvements. As a result, there is a growing emphasis on making these therapies accessible across diverse regions, positioning the market for robust growth as treatment paradigms evolve towards more personalized and effective solutions.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Primary Myelofibrosis Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- JAK Inhibitors
- Anemia-Directed Therapies
- Stem Cell Transplantation
- Supportive Care Therapies
- Others
Global Primary Myelofibrosis Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Branded Drugs
- Generic Drugs
Global Primary Myelofibrosis Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable/Parenteral
Global Primary Myelofibrosis Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Primary Myelofibrosis Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Ambulatory Care Centers
- Academic & Research Institutes
Global Primary Myelofibrosis Market Size & CAGR (2026-2033)
- North America (Treatment Type, Drug Type, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Drug Type, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Drug Type, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Drug Type, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Drug Type, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sallia
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gerone
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Geron Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sierra Oncology Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Constellation Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kartos Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CTI BioPharma Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Imago BioSciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
